In this issue:
Sacituzumab govitecan in metastatic triple-negative breast cancer
Tavokinogene telseplasmid in triple-negative breast tumours
Tool to individualise prognosis and predict chemotherapy benefit in early breast cancer
Endocrine therapy for male breast cancer
Mindfulness-based intervention in breast cancer
Gene signature to aid treatment decisions in early breast cancer
Breast cancer survival: distant vs. ipsilateral supraclavicular lymph node metastases
Palbociclib for high-risk invasive hormone receptor+, HER2– early breast cancer
Adjuvant pertuzumab and trastuzumab in early HER2+ breast cancer
Novel SERD, elacestrant, in oestrogen receptor+, HER2– advanced breast cancer
Please login below to download this issue (PDF)